8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Dec 8, 2025·SEC
IRadimed Corporation(IRMD)Earnings, Financials & Key Ratios
IRMD•NASDAQ
$102.30
58.5× P/E·Price updated Jul 6, 2026
AboutIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Show more
- Revenue$84M+14.4%
- EBITDA$29M+25.2%
- Net Income$22M+16.9%
- EPS (Diluted)1.75+16.7%
- Gross Margin76.75%-0.2%
- EBITDA Margin34.04%+9.4%
- Operating Margin31.2%+4.0%
- Net Margin26.82%+2.1%
- ROE24.78%+1.9%
IRMD Price & Volume
IRadimed Corporation (IRMD) stock price & volume — 10-year historical chart
Loading chart...
Premium MRI Device Margins Drive Operational Scaling
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Expanding
Profitability:Strong
Financial:Fortress
Cash Flow:Robust
Primary Risk:Regulatory 510(k) approval delays
Key Thesis Takeaways
- IRadimed maintains a robust growth trajectory by leveraging its specialized non-magnetic infusion pump technology to capture market share, evidenced by revenue growth from $17.5M in 2023Q4 to $22.0M in 2026Q1.
- The company's fortress balance sheet, now entirely debt-free, provides significant strategic optionality, though investors should monitor potential regulatory bottlenecks regarding 510(k) clearances that could impact future hardware cycles.
- While the current 0.73 PEG ratio suggests potential value, the firm's conservative capital deployment warrants further investigation into whether its $56.4M cash position could be more efficiently utilized to drive long-term shareholder returns.
Verdict Logic
the company's ability to maintain a 0.73 PEG ratio alongside a 35.9% FCF margin in 2026Q1 suggests that the current valuation is supported by high-quality, cash-generative growth.
IRMD Growth Metrics
IRadimed Corporation (IRMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.25%
5 Years21.45%
3 Years16.28%
TTM14.81%
Profit CAGR
10 Years11.56%
5 Years75.02%
3 Years20.56%
TTM19.34%
EPS CAGR
10 Years11.3%
5 Years73.91%
3 Years19.71%
TTM18.06%
Return on Capital
10 Years18.22%
5 Years22.95%
3 Years26.83%
Last Year27.76%
IRMD Recent Earnings
IRadimed Corporation (IRMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$0.49+16.7%
$0.42
Rev
$22M+3.1%
$21M
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.54+10.2%
$0.49
Rev
$23M+5.1%
$22M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.47-2.1%
$0.48
Rev
$21M-1.8%
$22M
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$0.49+8.9%
$0.45
Rev
$20M-0.4%
$20M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $0.49vs $0.42+16.7% | $22Mvs $21M+3.1% |
| Q1 2026 | Feb 10, 2026 | $0.54vs $0.49+10.2% | $23Mvs $22M+5.1% |
| Q4 2025 | Nov 3, 2025 | $0.47vs $0.48-2.1% | $21Mvs $22M-1.8% |
| Q3 2025 | Aug 1, 2025 | $0.49vs $0.45+8.9% | $20Mvs $20M-0.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for IRadimed Corporation (IRMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $102.30 | $1.31B | 58.46 | 14.43% | 26.82% | 24.78% | 1.14% | |
| $102.82 | $6.69B | 30.15 | 0.5% | 18.05% | 24.33% | — | |
| $21.21 | $1.21B | -12.33 | 37.22% | -31.82% | -27.7% | — | |
| $12.98 | $536.32M | -15.64 | -3.76% | -10% | -17.65% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $64.84 | $29.5B | 14.25 | 4.84% | 7.54% | 14.45% | — |
Compare IRMD vs Peers
IRadimed Corporation (IRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRMD SEC Filings & Documents
IRadimed Corporation (IRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IRMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRMD Frequently Asked Questions
IRadimed Corporation (IRMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is IRadimed Corporation's revenue?
IRadimed Corporation (IRMD) reported $86.3M in revenue for fiscal year 2025. This represents a 1023% increase from $7.7M in 2012.
How fast is IRadimed Corporation growing?
IRadimed Corporation (IRMD) grew revenue by 14.4% over the past year. This is steady growth.
Is IRMD profitable?
Yes, IRadimed Corporation (IRMD) is profitable, generating $23.6M in net income for fiscal year 2025 (26.8% net margin).
Dividend & Returns
Does IRMD pay dividends?
Yes, IRadimed Corporation (IRMD) pays a dividend with a yield of 1.14%. This makes it attractive for income-focused investors.
What is IRMD's return on equity?
IRadimed Corporation (IRMD) has a return on equity (ROE) of 24.8%. This is excellent, indicating efficient use of shareholder capital.
What is IRadimed Corporation's free cash flow?
IRadimed Corporation (IRMD) generated $24.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.